Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

A safety and pharmacokinetic trial assessing delivery of dapivirine from a vaginal ring in healthy women.

Nel A, Haazen W, Nuttall J, Romano J, Rosenberg Z, van Niekerk N.

AIDS. 2014 Jun 19;28(10):1479-87. doi: 10.1097/QAD.0000000000000280.

PMID:
24901365
2.

Pre-clinical development of a combination microbicide vaginal ring containing dapivirine and darunavir.

Murphy DJ, Desjardins D, Dereuddre-Bosquet N, Brochard P, Perrot L, Pruvost A, Le Grand R, Lagatie O, Vanhooren L, Feyaerts M, van Roey J, Malcolm RK.

J Antimicrob Chemother. 2014 Sep;69(9):2477-88. doi: 10.1093/jac/dku160. Epub 2014 May 26.

PMID:
24862093
3.

Safety, tolerability, and systemic absorption of dapivirine vaginal microbicide gel in healthy, HIV-negative women.

Nel AM, Coplan P, van de Wijgert JH, Kapiga SH, von Mollendorf C, Geubbels E, Vyankandondera J, Rees HV, Masenga G, Kiwelu I, Moyes J, Smythe SC.

AIDS. 2009 Jul 31;23(12):1531-8. doi: 10.1097/QAD.0b013e32832c413d.

PMID:
19550287
4.

Safety and availability of dapivirine (TMC120) delivered from an intravaginal ring.

Romano J, Variano B, Coplan P, Van Roey J, Douville K, Rosenberg Z, Temmerman M, Verstraelen H, Van Bortel L, Weyers S, Mitchnick M.

AIDS Res Hum Retroviruses. 2009 May;25(5):483-8. doi: 10.1089/aid.2008.0184.

PMID:
19388819
5.

Pharmacokinetics of 2 dapivirine vaginal microbicide gels and their safety vs. Hydroxyethyl cellulose-based universal placebo gel.

Nel AM, Smythe SC, Habibi S, Kaptur PE, Romano JW.

J Acquir Immune Defic Syndr. 2010 Oct;55(2):161-9. doi: 10.1097/QAI.0b013e3181e3293a.

PMID:
20574411
6.

The sheep as a model of preclinical safety and pharmacokinetic evaluations of candidate microbicides.

Holt JD, Cameron D, Dias N, Holding J, Muntendam A, Oostebring F, Dreier P, Rohan L, Nuttall J.

Antimicrob Agents Chemother. 2015 Jul;59(7):3761-70. doi: 10.1128/AAC.04954-14. Epub 2015 Apr 6.

7.

Safety, Acceptability and Adherence of Dapivirine Vaginal Ring in a Microbicide Clinical Trial Conducted in Multiple Countries in Sub-Saharan Africa.

Nel A, Bekker LG, Bukusi E, Hellstrӧm E, Kotze P, Louw C, Martinson F, Masenga G, Montgomery E, Ndaba N, van der Straten A, van Niekerk N, Woodsong C.

PLoS One. 2016 Mar 10;11(3):e0147743. doi: 10.1371/journal.pone.0147743. eCollection 2016.

8.

Safety and pharmacokinetics of dapivirine delivery from matrix and reservoir intravaginal rings to HIV-negative women.

Nel A, Smythe S, Young K, Malcolm K, McCoy C, Rosenberg Z, Romano J.

J Acquir Immune Defic Syndr. 2009 Aug 1;51(4):416-23.

PMID:
19623693
9.

Pharmacokinetic assessment of dapivirine vaginal microbicide gel in healthy, HIV-negative women.

Nel AM, Coplan P, Smythe SC, McCord K, Mitchnick M, Kaptur PE, Romano J.

AIDS Res Hum Retroviruses. 2010 Nov;26(11):1181-90. doi: 10.1089/aid.2009.0227. Epub 2010 Sep 21.

PMID:
20854207
10.

A phase 1 randomized placebo-controlled safety and pharmacokinetic trial of a tenofovir disoproxil fumarate vaginal ring.

Keller MJ, Mesquita PM, Marzinke MA, Teller R, Espinoza L, Atrio JM, Lo Y, Frank B, Srinivasan S, Fredricks DN, Rabe L, Anderson PL, Hendrix CW, Kiser PF, Herold BC.

AIDS. 2016 Mar 13;30(5):743-51. doi: 10.1097/QAD.0000000000000979.

11.

A Phase 1 Trial to Assess the Safety, Acceptability, Pharmacokinetics, and Pharmacodynamics of a Novel Dapivirine Vaginal Film.

Bunge KE, Dezzutti CS, Rohan LC, Hendrix CW, Marzinke MA, Richardson-Harman N, Moncla BJ, Devlin B, Meyn LA, Spiegel HM, Hillier SL.

J Acquir Immune Defic Syndr. 2016 Apr 15;71(5):498-505. doi: 10.1097/QAI.0000000000000897.

12.

Phase 1 Safety, Pharmacokinetics, and Pharmacodynamics of Dapivirine and Maraviroc Vaginal Rings: A Double-Blind Randomized Trial.

Chen BA, Panther L, Marzinke MA, Hendrix CW, Hoesley CJ, van der Straten A, Husnik MJ, Soto-Torres L, Nel A, Johnson S, Richardson-Harman N, Rabe LK, Dezzutti CS.

J Acquir Immune Defic Syndr. 2015 Nov 1;70(3):242-9. doi: 10.1097/QAI.0000000000000702.

13.

Safety and Efficacy of a Dapivirine Vaginal Ring for HIV Prevention in Women.

Nel A, van Niekerk N, Kapiga S, Bekker LG, Gama C, Gill K, Kamali A, Kotze P, Louw C, Mabude Z, Miti N, Kusemererwa S, Tempelman H, Carstens H, Devlin B, Isaacs M, Malherbe M, Mans W, Nuttall J, Russell M, Ntshele S, Smit M, Solai L, Spence P, Steytler J, Windle K, Borremans M, Resseler S, Van Roey J, Parys W, Vangeneugden T, Van Baelen B, Rosenberg Z; Ring Study Team.

N Engl J Med. 2016 Dec 1;375(22):2133-2143.

14.

Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women.

Baeten JM, Palanee-Phillips T, Brown ER, Schwartz K, Soto-Torres LE, Govender V, Mgodi NM, Matovu Kiweewa F, Nair G, Mhlanga F, Siva S, Bekker LG, Jeenarain N, Gaffoor Z, Martinson F, Makanani B, Pather A, Naidoo L, Husnik M, Richardson BA, Parikh UM, Mellors JW, Marzinke MA, Hendrix CW, van der Straten A, Ramjee G, Chirenje ZM, Nakabiito C, Taha TE, Jones J, Mayo A, Scheckter R, Berthiaume J, Livant E, Jacobson C, Ndase P, White R, Patterson K, Germuga D, Galaska B, Bunge K, Singh D, Szydlo DW, Montgomery ET, Mensch BS, Torjesen K, Grossman CI, Chakhtoura N, Nel A, Rosenberg Z, McGowan I, Hillier S; MTN-020–ASPIRE Study Team.

N Engl J Med. 2016 Dec 1;375(22):2121-2132. Epub 2016 Feb 22.

15.

Dose-ranging phase 1 study of TMC120, a promising vaginal microbicide, in HIV-negative and HIV-positive female volunteers.

Jespers VA, Van Roey JM, Beets GI, Buvé AM.

J Acquir Immune Defic Syndr. 2007 Feb 1;44(2):154-8.

PMID:
17106275
16.

Development of dapivirine vaginal ring for HIV prevention.

Devlin B, Nuttall J, Wilder S, Woodsong C, Rosenberg Z.

Antiviral Res. 2013 Dec;100 Suppl:S3-8. doi: 10.1016/j.antiviral.2013.09.025. Epub 2013 Nov 1. Review.

PMID:
24188702
17.

A randomized male tolerance study of dapivirine gel following multiple topical penile exposures (MTN 012/IPM 010).

Cranston RD, Hoesley C, Carballo-Diéguez A, Hendrix CW, Husnik M, Levy L, Hall W, Soto-Torres L, Nel AM.

AIDS Res Hum Retroviruses. 2014 Feb;30(2):184-9. doi: 10.1089/AID.2013.0170. Epub 2013 Oct 26.

18.

Characteristics of Women Enrolled into a Randomized Clinical Trial of Dapivirine Vaginal Ring for HIV-1 Prevention.

Palanee-Phillips T, Schwartz K, Brown ER, Govender V, Mgodi N, Kiweewa FM, Nair G, Mhlanga F, Siva S, Bekker LG, Jeenarain N, Gaffoor Z, Martinson F, Makanani B, Naidoo S, Pather A, Phillip J, Husnik MJ, van der Straten A, Soto-Torres L, Baeten J.

PLoS One. 2015 Jun 10;10(6):e0128857. doi: 10.1371/journal.pone.0128857. eCollection 2015.

19.

Long-term, controlled release of the HIV microbicide TMC120 from silicone elastomer vaginal rings.

Malcolm RK, Woolfson AD, Toner CF, Morrow RJ, McCullagh SD.

J Antimicrob Chemother. 2005 Nov;56(5):954-6. Epub 2005 Sep 9.

PMID:
16155060
20.

Concentrations of dapivirine in the rhesus macaque and rabbit following once daily intravaginal administration of a gel formulation of [14C]dapivirine for 7 days.

Nuttall JP, Thake DC, Lewis MG, Ferkany JW, Romano JW, Mitchnick MA.

Antimicrob Agents Chemother. 2008 Mar;52(3):909-14. Epub 2007 Dec 17.

Supplemental Content

Support Center